Alex A Adjei

Summary

Affiliation: Roswell Park Cancer Institute
Country: USA

Publications

  1. pmc Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers
    Alex A Adjei
    Roswell Park Cancer Institute, Buffalo, New York, USA
    Oncologist 16:788-99. 2011
  2. doi request reprint Novel designs and end points for phase II clinical trials
    Alex A Adjei
    Roswell Park Cancer Institute, Buffalo, New York, USA
    Clin Cancer Res 15:1866-72. 2009
  3. doi request reprint Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review
    Alex A Adjei
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Clin Lung Cancer 12:212-7. 2011
  4. ncbi request reprint Cancer symposium for the practitioner: introduction to solid tumors
    Alex A Adjei
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Mayo Clin Proc 82:107-9. 2007
  5. pmc Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
    Alex A Adjei
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Clin Oncol 26:2139-46. 2008
  6. ncbi request reprint Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study
    Araba A Adjei
    Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Thorac Oncol 5:1346-53. 2010
  7. pmc Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426
    Alex A Adjei
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Clin Oncol 28:614-9. 2010
  8. ncbi request reprint Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer
    Alex A Adjei
    Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Clin Cancer Res 13:2684-91. 2007
  9. ncbi request reprint Novel small-molecule inhibitors of the vascular endothelial growth factor receptor
    Alex A Adjei
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Clin Lung Cancer 8:S74-8. 2007
  10. ncbi request reprint K-ras as a target for lung cancer therapy
    Alex A Adjei
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Thorac Oncol 3:S160-3. 2008

Collaborators

Detail Information

Publications88

  1. pmc Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers
    Alex A Adjei
    Roswell Park Cancer Institute, Buffalo, New York, USA
    Oncologist 16:788-99. 2011
    ....
  2. doi request reprint Novel designs and end points for phase II clinical trials
    Alex A Adjei
    Roswell Park Cancer Institute, Buffalo, New York, USA
    Clin Cancer Res 15:1866-72. 2009
    ..Third, rational incorporation of biomarkers into phase II trials should be encouraged. Last, novel imaging modalities will be critical in evaluating the clinical benefit of new cytostatic agents...
  3. doi request reprint Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review
    Alex A Adjei
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Clin Lung Cancer 12:212-7. 2011
    ..Currently, minimal data are available describing the long-term safety and tolerability of sorafenib in patients with NSCLC...
  4. ncbi request reprint Cancer symposium for the practitioner: introduction to solid tumors
    Alex A Adjei
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Mayo Clin Proc 82:107-9. 2007
  5. pmc Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
    Alex A Adjei
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Clin Oncol 26:2139-46. 2008
    ..To assess the tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of the mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancer...
  6. ncbi request reprint Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study
    Araba A Adjei
    Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Thorac Oncol 5:1346-53. 2010
    ..To correlate polymorphisms in genes involved in the transport, activation, and inactivation of pemetrexed with the outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with pemetrexed...
  7. pmc Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426
    Alex A Adjei
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Clin Oncol 28:614-9. 2010
    ....
  8. ncbi request reprint Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer
    Alex A Adjei
    Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Clin Cancer Res 13:2684-91. 2007
    ..To evaluate the combination of sorafenib and gefitinib in patients with advanced non-small cell lung cancer...
  9. ncbi request reprint Novel small-molecule inhibitors of the vascular endothelial growth factor receptor
    Alex A Adjei
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Clin Lung Cancer 8:S74-8. 2007
    ..There are several small-molecule inhibitors of tyrosine kinase activity of VEGF receptors in clinical trials. These are discussed in this review...
  10. ncbi request reprint K-ras as a target for lung cancer therapy
    Alex A Adjei
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Thorac Oncol 3:S160-3. 2008
    ..However, many of these agents have multiple targets, and their antitumor effects may not be due to K-ras inhibition. To date, no selective, specific inhibitor of the K-ras pathway is available for routine clinical use...
  11. pmc A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528
    Grace K Dy
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
    J Thorac Oncol 8:79-88. 2013
    ..The purpose of this study was to assess the safety and efficacy of gemcitabine and carboplatin with (arm A) or without (arm B) daily oral cediranib as first-line therapy for advanced non-small-cell lung cancer...
  12. doi request reprint A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326
    Grace K Dy
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer 116:5686-93. 2010
    ..The current study was conducted to assess the efficacy and toxicity of sorafenib as front-line therapy in patients with stage IIIB (pleural effusion) or IV nonsmall cell lung cancer (NSCLC)...
  13. doi request reprint Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer
    Wen Wee Ma
    Roswell Park Cancer Institute, Buffalo, New York University of Colorado Cancer Center, Aurora, CO 80045, USA
    Clin Cancer Res 18:2048-55. 2012
    ..This phase I study aimed to determine the recommended phase II dose (RPTD) of the combination of rigosertib and gemcitabine in patients with cancer...
  14. ncbi request reprint A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors
    Grace K Dy
    Department of Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 55:522-30. 2005
    ..The present study was undertaken to evaluate the efficacy, toxicity, and pharmacokinetics of gemcitabine and pemetrexed when pemetrexed is administered immediately after gemcitabine...
  15. doi request reprint Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study
    Thanyanan Reungwetwattana
    Mayo Clinic Cancer Center, Rochester MN, USA
    J Thorac Oncol 7:919-22. 2012
    ..In an effort to evaluate the single agent activity of temsirolimus in previously untreated non-small-cell lung cancer, the North Central Cancer Treatment Group undertook a frontline "window-of-opportunity" study...
  16. doi request reprint Novel agents on the horizon for cancer therapy
    Wen W Ma
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
    CA Cancer J Clin 59:111-37. 2009
    ..This review also highlights the pipeline of rationally designed drugs in clinical development that have the potential to impact clinical care in the near future...
  17. ncbi request reprint Farnesyltransferase inhibitors in breast cancer therapy
    Grace K Dy
    Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Invest 20:30-7. 2002
    ..Thus, the role of other protein targets in mediating the antitumor effect of FTIs is being elucidated. This article reviews current data on the use of FTIs in breast cancer...
  18. ncbi request reprint Angiogenesis inhibitors in lung cancer: a promise fulfilled
    Grace K Dy
    Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lung Cancer 7:S145-9. 2006
    ..In this review, we will discuss various aspects of this pivotal trial and highlight issues relevant to angiogenesis inhibition in the treatment of non-small-cell lung cancer...
  19. doi request reprint Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer
    Huanjie Shao
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
    J Thorac Oncol 6:998-1005. 2011
    ..We aim to demonstrate the role of SPARC expression as biomarker for treatment selection using ABX in NSCLC and to evaluate the presence of synergistic antitumor effect when a demethylating agent is combined with ABX...
  20. doi request reprint Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib
    Grace K Dy
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Invest New Drugs 31:891-9. 2013
    ....
  21. pmc Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia
    Scott H Kaufmann
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Haematologica 96:1619-26. 2011
    ..We report here the results of a phase I and pharmacological study of the cytarabine + tanespimycin combination in adults with recurrent or refractory acute leukemia...
  22. doi request reprint Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo
    Huanjie Shao
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Hepatol 56:176-83. 2012
    ..Therefore, dual targeting of mTORC1/C2 should be more efficient in suppressing AKT activity and in enhancing the anti-tumor activity of HDACi in HCC...
  23. pmc Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials
    Ming Wen An
    Department of Mathematics, Vassar College, Poughkeepsie, New York, USA
    Clin Cancer Res 17:6592-9. 2011
    ..The categorical definition of response assessed via the Response Evaluation Criteria in Solid Tumors has documented limitations. We sought to identify alternative metrics for tumor response that improve prediction of overall survival...
  24. ncbi request reprint Complementary and alternative medicine use by patients enrolled onto phase I clinical trials
    Grace K Dy
    Division of Medical Oncology, Department of Medicine, Mayo Foundation and Mayo Clinic College of Medicine, Rochester, MN, USA
    J Clin Oncol 22:4810-5. 2004
    ..To describe the prevalence, clinical characteristics, and pattern of use of complementary and alternative medicine (CAM) in patients enrolled onto phase I trials...
  25. ncbi request reprint Analysis of second primary lung cancers in the SEER database
    Amrit Bhaskarla
    Department of Thoracic Surgery, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    J Surg Res 162:1-6. 2010
    ..We also sought to study the outcomes of synchronous second non-small-cell lung cancers (NSCLCs), classified as stage IVA (M1A) according to the seventh edition of the TNM staging for lung cancer...
  26. doi request reprint Emerging therapeutic targets in non-small cell lung cancer
    Grace K Dy
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Proc Am Thorac Soc 6:218-23. 2009
    ..This review highlights the biological targets relevant in the treatment of non-small cell lung cancer...
  27. pmc Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer
    Aaron S Mansfield
    aDepartment of Medical Oncology, Mayo Clinic, Rochester, Minnesota bDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida cDepartment of Internal Medicine, Greater Baltimore Medical Center, Baltimore, Maryland dDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
    Anticancer Drugs 24:1079-83. 2013
    ..In summary, this phase I study was successful in identifying ATM 50 mg intramuscularly weekly as the MTD. Future clinical investigations targeting PKCι are currently in progress...
  28. pmc Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells
    Chunrong Yu
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Neuro Oncol 10:309-19. 2008
    ..This combination regimen warrants further preclinical and possible clinical study for glioma patients...
  29. doi request reprint Systemic cancer therapy: evolution over the last 60 years
    Grace K Dy
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Cancer 113:1857-87. 2008
    ..The key approaches and evidence pertinent to the clinical development of these novel agents are presented in this review...
  30. ncbi request reprint Novel targets for lung cancer therapy: part II
    Grace K Dy
    Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 20:3016-28. 2002
    ..Future approaches to treatment are suggested...
  31. ncbi request reprint Thoracoscopic organ suffusion for regional lung chemotherapy (preliminary results)
    Todd L Demmy
    Department of Thoracic Surgery, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Ann Thorac Surg 88:385-90; discussion 390-1. 2009
    ..After promising preclinical studies using a thoracoscopic regional lung chemotherapy technique less morbid than open perfusion methods, we initiated a Phase I clinical study...
  32. ncbi request reprint Small cell lung cancer
    Taimur Sher
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Mayo Clin Proc 83:355-67. 2008
    ..Other novel agents such as bevacizumab have shown promising early results and are being evaluated in larger trials...
  33. doi request reprint Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer
    Grace K Dy
    Roswell Park Cancer Institute, Buffalo, New York The Oncology Institute of Hope and Innovation, Anaheim, California Rochester General Hospital, Rochester, New York and Department of Medicine, University of Michigan, Ann Arbor, Michigan
    J Thorac Oncol 9:222-30. 2014
    ..Pathologic complete response (pCR) with neoadjuvant chemotherapy is associated with improved survival in many solid tumors. We evaluated pCR rate of cisplatin with pemetrexed in non-small-cell lung cancer...
  34. ncbi request reprint Understanding, recognizing, and managing toxicities of targeted anticancer therapies
    Grace K Dy
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
    CA Cancer J Clin 63:249-79. 2013
    ..These toxicities need to be recognized, prevented, and optimally managed...
  35. ncbi request reprint Targeting multiple signal transduction pathways in lung cancer
    Alex A Adjei
    Division of Medical Oncology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lung Cancer 7:S39-44. 2005
    ..These inhibitors include ZD6474, SU11248, AEE 788, sorafenib, vatalanib, and AG-013736...
  36. ncbi request reprint Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia
    Scott H Kaufmann
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55901, USA
    Clin Cancer Res 11:6641-9. 2005
    ..To assess the maximum tolerated dose, toxicities, pharmacokinetics, and antileukemic activity of topotecan and carboplatin in adults with recurrent or refractory acute leukemias...
  37. ncbi request reprint Novel targets for lung cancer therapy: part I
    Grace K Dy
    Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 20:2881-94. 2002
    ..In this article, agents inhibiting growth factor receptors and various molecules downstream of activated signaling cascades, such as cytoplasmic second messengers, are described...
  38. ncbi request reprint Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trials
    Sumithra J Mandrekar
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Thorac Oncol 1:556-63. 2006
    ..This pooled analysis was performed to examine the impact of pretreatment factors on severe (grade 3 or higher) adverse events (AE) in patients with advanced stage non-small cell lung cancer (NSCLC)...
  39. ncbi request reprint The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy
    Vassiliki Papadimitrakopoulou
    MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 1:749-51. 2006
    ..We review current information on the therapeutic manipulation of these targets and describe early clinical data in lung cancer...
  40. ncbi request reprint An overview of farnesyltransferase inhibitors and their role in lung cancer therapy
    Alex A Adjei
    Department of Oncology, Mayo Clinic, 200 First Street S W, Rochester, MN 55905, USA
    Lung Cancer 41:S55-62. 2003
    ..However, current evidence suggests that the antitumor activity of FTIs may be ras-independent. This article reviews preclinical and clinical data pertinent to the use of FTIs in lung cancer...
  41. ncbi request reprint The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer
    Steven E Schild
    Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 110:363-8. 2007
    ....
  42. ncbi request reprint BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins
    Bret B Friday
    Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Cancer Res 68:6145-53. 2008
    ..These data suggest an approach to identifying cells that may be sensitive to AZD6244 and other MEK inhibitors...
  43. ncbi request reprint Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors
    Paul Haluska
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 13:5834-40. 2007
    ..This phase I study was undertaken to define the maximum tolerated dose, safety, and pharmacokinetic profile of CP-751,871...
  44. ncbi request reprint Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?
    Corey J Langer
    Thoracic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Clin Lung Cancer 9:85-91. 2008
    ..These efforts focus on radiation dose escalation using image-guided radiation therapy as well as newer cytotoxic agents (eg, pemetrexed) and targeted therapies (eg, cetuximab, bevacizumab, and etc) thus far unexplored in this setting...
  45. ncbi request reprint Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51)
    Elizabeth A Johnson
    Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
    Lung Cancer 60:200-7. 2008
    ....
  46. ncbi request reprint Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy
    Bret B Friday
    Department of Oncology, Mayo Clinic, Rochester, MN, USA
    Clin Cancer Res 14:342-6. 2008
    ..Herein, we review the MAPK pathway, the development of small-molecule MEK inhibitors, and the results obtained to date with MEK inhibitors in human cancer trials...
  47. pmc Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship
    Julian R Molina
    Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:584-94. 2008
    ....
  48. ncbi request reprint Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization
    Xue Wei Meng
    Divisions of Oncology Research, Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Biol Chem 282:29831-46. 2007
    ..Collectively, these observations not only suggest a model in which Mcl-1 confers TRAIL resistance by serving as a buffer for Bak, Bim, and Puma, but also identify sorafenib as a potential modulator of TRAIL sensitivity...
  49. ncbi request reprint A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer
    Grzegorz S Nowakowski
    Department of Oncology, Cancer Center Statistics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 12:6087-93. 2006
    ....
  50. ncbi request reprint Advances in chemotherapy of non-small cell lung cancer
    Julian R Molina
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Chest 130:1211-9. 2006
    ....
  51. ncbi request reprint Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly
    Steven E Schild
    Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 103:2349-54. 2005
    ..No difference in survival was identified between the two arms. The current analysis examined the relation between age and outcome for patients treated during this trial...
  52. ncbi request reprint A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer
    Grace K Dy
    Department of Oncology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Clin Cancer Res 11:1877-83. 2005
    ..This phase I study was conducted to determine the toxicities, pharmacokinetics, and pharmacodynamics of BMS-214662, a farnesyl transferase inhibitor, in combination with paclitaxel and carboplatin, in patients with advanced solid tumors...
  53. ncbi request reprint Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
    John Rinehart
    University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Clin Oncol 22:4456-62. 2004
    ....
  54. ncbi request reprint Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent
    Alex A Adjei
    Mayo Clinic and Foundation, Departments of Oncology, Rochester, Minnesota, USA
    Clin Cancer Res 10:4276s-4280s. 2004
    ..Low level dietary supplement of folic acid and vitamin B12 has significantly decreased the mucosal and bone marrow toxicity of pemetrexed without compromising its antitumor effect...
  55. ncbi request reprint Novel agents in the treatment of lung cancer: conference summary statement
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Cancer Res 10:4199s-4204s. 2004
  56. ncbi request reprint Farnesyltransferase inhibitors
    Said M Sebti
    H Lee Moffitt Cancer Center, Tampa, FL, USA
    Semin Oncol 31:28-39. 2004
    ..Activity has been shown in hematologic malignancies (acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome), breast cancer, and glioma. Several combination studies of FTIs and standard cytotoxic agents are ongoing...
  57. ncbi request reprint Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma
    Melissa Alsina
    Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute and Department of Oncology, University of South Florida, Tampa, FL 33612, USA
    Blood 103:3271-7. 2004
    ..We conclude that tipifarnib is tolerable, can induce disease stabilization, and can inhibit farnesylation and oncogenic/tumor survival pathways...
  58. ncbi request reprint The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy
    Julian R Molina
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Clin Lung Cancer 5:21-7. 2003
    ..In this review, the pharmacology and clinical activity of pemetrexed in NSCLC cancer is discussed...
  59. ncbi request reprint Novel anticancer agents in clinical development
    Alex A Adjei
    Mayo Clinic and Foundation Rochester, Minnesota 55905, USA
    Cancer Biol Ther 2:S5-15. 2003
    ..This review will highlight promising rationally designed, target-based agents in clinical development, as well as the unique challenges involved in their successful development...
  60. ncbi request reprint Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors
    Matthew P Goetz
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 21:3761-9. 2003
    ..Additionally, we investigated the effect of CPT-11 on oxaliplatin pharmacokinetics...
  61. ncbi request reprint A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer
    Alex A Adjei
    Mayo Clinic and Foundation, Departments of Oncology and Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 9:2520-6. 2003
    ..This Phase I study was undertaken to define the toxicity, pharmacodynamics, and maximum tolerated dose of the combination of R115777, a farnesyl transferase inhibitor, with gemcitabine and cisplatin in patients with advanced solid tumors...
  62. ncbi request reprint A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer
    E Claire Dees
    Division of Hematology and Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Invest New Drugs 21:75-84. 2003
    ..Pharmacokinetic analysis showed that sequence does not impact on the pharmacokinetics of PZA when given in combination with cisplatin...
  63. ncbi request reprint Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer
    Alex A Adjei
    Department of Onclogy, Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 21:1760-6. 2003
    ..This phase II study was undertaken to define the efficacy and pharmacodynamics of R115777, a farnesyl transferase inhibitor, in the first-line treatment of patients with advanced non-small-cell lung cancer...
  64. ncbi request reprint Preclinical and clinical studies with combinations of pemetrexed and gemcitabine
    Alex A Adjei
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Semin Oncol 29:30-4. 2002
    ..Phase II studies of this combination are being performed in breast and non-small cell lung cancer. In addition, a phase III study in pancreatic cancer is ongoing...
  65. ncbi request reprint A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer
    Alex A Adjei
    Department of Oncology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 9:115-23. 2003
    ..The purpose of this study was to define the toxicity, pharmacokinetics, and clinical activity of the combination of ISIS 2503, an oligodeoxynucleotide antisense inhibitor of H-ras, and gemcitabine in patients with advanced solid tumors...
  66. ncbi request reprint Inhibitors of the ras oncogene as therapeutic targets
    Irene M Ghobrial
    Division of Medical Oncology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Hematol Oncol Clin North Am 16:1065-88. 2002
    ....
  67. ncbi request reprint A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer
    Alex A Adjei
    Division of Medical Oncology, Mayo Clinic, Mayo Graduate School, Rochester, MN 55905, USA
    Invest New Drugs 20:297-304. 2002
    ..Subsequent studies revealed that PZA inhibits removal of platinum-DNA adducts in cultured A549 cells. Based on these results, we undertook a phase I study of the combination of PZA and carboplatin (CBDCA)...
  68. ncbi request reprint A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer
    Grace K Dy
    Mayo Clinic, Rochester, Minnesota, 55905, USA
    Clin Cancer Res 11:3410-6. 2005
    ..To define the toxicities, pharmacodynamics, and clinical activity of the proteasome inhibitor, PS-341 (bortezomib), in patients with advanced malignancies...
  69. ncbi request reprint A phase II study of bortezomib in the treatment of metastatic malignant melanoma
    Svetomir N Markovic
    Melanoma Study Group, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 103:2584-9. 2005
    ..Bortezomib is a proteasome inhibitor with manageable clinical toxicity and laboratory evidence of anti-melanoma activity. Therefore, it was considered for clinical testing in patients with metastatic melanoma...
  70. ncbi request reprint Targeting apoptosis pathways in cancer therapy
    Irene M Ghobrial
    Division of Hematology, Department of Internal Medicine, University of Pittsburgh, PA, USA
    CA Cancer J Clin 55:178-94. 2005
    ..This article reviews the current understanding of the apoptotic pathways, including the extrinsic (cytoplasmic) and intrinsic (mitochondrial) pathways, and the agents being developed to target these pathways...
  71. ncbi request reprint Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways
    Chunrong Yu
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Mol Cancer Ther 5:2378-87. 2006
    ..Further clinical development of this combination seems warranted...
  72. ncbi request reprint What is the right dose? The elusive optimal biologic dose in phase I clinical trials
    Alex A Adjei
    J Clin Oncol 24:4054-5. 2006
  73. ncbi request reprint Novel combinations based on epidermal growth factor receptor inhibition
    Alex A Adjei
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 12:4446s-4450s. 2006
    ..A brief overview of some of these pathways (mammalian target of rapamycin, vascular endothelial growth factor receptor, and ras/mitogen-activated protein kinase signaling) is provided in this review...
  74. ncbi request reprint Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, Boston 02114, and University of Colorado Cancer Center, Aurora, USA
    Clin Cancer Res 12:4365s-4371s. 2006
  75. ncbi request reprint A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials
    Sumithra J Mandrekar
    Mayo Clinic College of Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 107:781-92. 2006
    ....
  76. ncbi request reprint A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer
    Julian R Molina
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer Invest 24:382-9. 2006
    ..This Phase II study was undertaken to define the efficacy and toxicity of the combination of docetaxel and irinotecan for the second-line treatment of non-small cell lung cancer (NSCLC)...
  77. ncbi request reprint Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents
    Jocelyn Holash
    Regeneron Pharmaceuticals, Tarrytown, NY, USA
    Cancer Metastasis Rev 25:243-52. 2006
  78. ncbi request reprint Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors
    Charles Erlichman
    Department of Oncology, Mayo Clinic, Rochester, MN 55902, USA
    J Clin Oncol 24:2252-60. 2006
    ....
  79. ncbi request reprint The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy
    Alex A Adjei
    Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Clin Lung Cancer 7:221-3. 2005
    ..The most promising approach to date appears to be the inhibition of mitogen-activated ERK kinase or MEK. In this review, the potential utility of MEK inhibitors in the therapy of lung cancer is discussed...
  80. ncbi request reprint Obstacles and opportunities in the clinical development of targeted therapeutics
    Grace K Dy
    Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Prog Drug Res 63:19-41. 2005
  81. ncbi request reprint Sequencing bortezomib with chemotherapy and targeted agents
    Alex A Adjei
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lung Cancer 7:S56-8. 2005
    ..This review provides an overview of selected interactions between bortezomib and other anticancer agents preclinically and in early clinical trials...
  82. ncbi request reprint K-ras as a target for cancer therapy
    Bret B Friday
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Biochim Biophys Acta 1756:127-44. 2005
    ....
  83. ncbi request reprint Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer
    Cynthia X Ma
    Department of Oncology and Medicine, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:5929-37. 2005
    ..A randomized three-arm phase II study was undertaken to evaluate the optimum administration schedule of pemetrexed and gemcitabine in chemotherapy-naïve patients with non-small-cell lung cancer...
  84. ncbi request reprint Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points
    Keith C Bible
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesotta 55905, USA
    Clin Cancer Res 11:5935-41. 2005
    ....
  85. ncbi request reprint Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution
    Karin F Giordano
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Lung Cancer 49:209-15. 2005
    ....
  86. ncbi request reprint Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
    Patricia M LoRusso
    Barbara Ann Karmanos Cancer Institute, 4100 John R 4 HWCRC, Room 4206, Detroit, MI 48201, USA
    J Clin Oncol 23:5281-93. 2005
    ....
  87. ncbi request reprint The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006
    Chunrong Yu
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Oncogene 24:6861-9. 2005
    ..Conversely, Mcl-1 downregulation by short hairpin RNA enhanced BAY 43-9006-induced apoptosis. Collectively, these findings demonstrate that drug-induced Mcl-1 downregulation contributes to the proapoptotic effects of BAY 43-9006...
  88. ncbi request reprint Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors
    Alex A Adjei
    Mayo Clinic and Foundation, Department of Oncology, Rochester, MN 55905, USA
    J Clin Oncol 20:1683-91. 2002
    ..To compare the pharmacokinetics of continuous venous infusion (CVI) fluorouracil (5-FU) with that of oral eniluracil/5-FU and to describe toxicities and clinical activity of prolonged oral administration of eniluracil/5-FU...